Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure

Author(s): Sohail Qayyum , Huijun Dong , Dianne Kovacic , Sidra Sohail , Bradford Waters , Camille Thornton , Cathy E. Corbett .

Journal Name: Current Drug Safety

Volume 7 , Issue 5 , 2012

Become EABM
Become Reviewer


A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.

Keywords: Drug induced hepatic failure, AIDS combination therapy, antiretroviral, NNRTI, Emtricitabine, hepatic failure, hepatotoxicity, gonococcal, syphilis, genital herpes

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [391 - 393]
Pages: 3
DOI: 10.2174/1574886311207050013
Price: $58

Article Metrics

PDF: 9